Pfizer names Cecile Guegan Interim CFO as Dave Denton steps down

Dave Denton, Chief Financial Officer, will step down from his current role and leave Pfizer on August 15

by e4m Staff
Published: Jun 20, 2026 8:11 AM | 2 min read

Pfizer Inc. CFO Dave Denton will resign from his position effective August 15 to pursue a new opportunity in the consumer goods sector.
Cecile Guegan, currently Senior Vice President of Finance for the Global Biopharmaceutical Business, has been appointed Interim CFO starting August 16 while the company searches for a permanent replacement.
CEO Albert Bourla praised Denton's contributions to Pfizer's financial health and key business transactions, while expressing confidence in Guegan's capabilities to lead the finance organization.
Guegan has over 20 years of experience at Pfizer and is responsible for financial operations and reporting across the company's biopharmaceutical business.

Pfizer Inc. announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search.

Dave and Cecile will work together to ensure a seamless transition.

“Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven, and Metsera, that will serve Pfizer well for years to come. We wish him the very best as he returns to the consumer goods industry,” said Albert Bourla, Chairman and Chief Executive Officer. “Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organization and keep us focused on what matters most — executing our strategy and delivering for patients and shareholders."

“It has been an honor and privilege to work alongside Albert for Pfizer, an iconic and purpose-driven company, during such a meaningful time in its history,” said Dave Denton, Executive Vice President and Chief Financial Officer. “Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward."

Cecile brings more than two decades of experience at Pfizer. In her current role, she is directly responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. She has strong financial judgement and a proven track record of leading important enterprise initiatives, including the integration of Seagen into Pfizer in 2024.